Budigalimab
- Generic Name
- Budigalimab
- Drug Type
- Biotech
- CAS Number
- 2098225-93-3
- Unique Ingredient Identifier
- 6VDO4TY3OO
- Background
Budigalimab is under investigation in clinical trial NCT04807972 (Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 Is Administered in Combination With IV Modified FOLFIRINOX (Mffx) With or Without IV Budigalimab Compared to Mffx in Adult Participants With Untreated Pancreatic Cancer Metastasis).
A Study of SC-006 and in Combination With ABBV-181 in Subjects With Advanced Colorectal Cancer
- First Posted Date
- 2017-01-30
- Last Posted Date
- 2020-02-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 29
- Registration Number
- NCT03035279
- Locations
- ๐บ๐ธ
University of Michigan Hospitals /ID# 167101, Ann Arbor, Michigan, United States
๐บ๐ธMemorial Sloan Kettering Cancer Center /ID# 160881, New York, New York, United States
๐บ๐ธMayo Clinic - Rochester /ID# 160884, Rochester, Minnesota, United States
A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2016-12-22
- Last Posted Date
- 2022-04-14
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 182
- Registration Number
- NCT03000257
- Locations
- ๐บ๐ธ
South Texas Accelerated Research Therapeutics /ID# 157378, San Antonio, Texas, United States
๐บ๐ธThe University of Chicago Medical Center /ID# 157375, Chicago, Illinois, United States
๐บ๐ธVirginia Cancer Specialists - Fairfax /ID# 157377, Fairfax, Virginia, United States
A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumors Cancer
- Interventions
- First Posted Date
- 2016-12-12
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 163
- Registration Number
- NCT02988960
- Locations
- ๐จ๐ฆ
University Health Network_Princess Margaret Cancer Centre /ID# 200819, Toronto, Ontario, Canada
๐บ๐ธThe Angeles Clinic and Researc /ID# 156324, Los Angeles, California, United States
๐บ๐ธThe University of Chicago Medical Center /ID# 155264, Chicago, Illinois, United States
A Study of ABT-165 in Subjects With Solid Tumors
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2013-09-19
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 101
- Registration Number
- NCT01946074
- Locations
- ๐บ๐ธ
HonorHealth Research Institute - Pima /ID# 105677, Scottsdale, Arizona, United States
๐บ๐ธUniversity of California, Los Angeles /ID# 141389, Los Angeles, California, United States
๐บ๐ธScottsdale Healthcare /ID# 105678, Scottsdale, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.